Dr. Janet McGill is Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine, and attending physician at Barnes-Jewish Hospital in St. Louis, Missouri. She is currently the principal investigator of the NIH funded GRADE study and the Insulin-Only Bionic Pancreas Pivotal Trial. She is a sub-investigator on the RADIANT study, which hopes to discover genetic causes of diabetes with atypical features through deep phenotyping and genotyping. Dr. McGill has conducted over 220 clinical trials in type 1 and type 2 diabetes studying new treatments and complications such as hypertension, hyperlipidemia, nephropathy, neuropathy and retinopathy. She was the PI of the NIH funded PERL study, “Preventing Early Renal Loss in Type 1 Diabetes” and a CGM sub-study, also the recently published WISDM study. She led the Washington University site for the T1D Exchange Clinic Registry, and was the PI for several T1D Exchange clinical trials and registry studies. Dr. McGill has served on steering committees and data safety and monitoring boards for long-term outcome studies, both NIH and industry sponsored, and leads data safety committees locally for investigator-initiated studies.

Dr. McGill has published over 200 peer-reviewed articles, numerous commentaries and editorials, 25 chapters, and she has edited four books, including the recently published books, Atypical Diabetes and the Washington Manual, Endocrine Subspecialty Consult, fourth edition. She has served on the editorial boards of several journals and has lectured nationally and internationally on diabetes and related topics. She served on the board of directors of AACE and ACE, and is active in the Endocrine Society and ADA. She is a member of AOA, and has received the Distinguished Clinician Award, the Alumni Achievement Award and the Endocrine Fellows’ Teaching Award from her peers at Washington University.